期刊文献+

乳腺黏液癌与普通型乳腺浸润性导管癌临床病理特征和ER、PR、P53、C-erbB-2、Ki-67表达差异分析 被引量:10

The clinicopathological characteristics and expression of ER,PR,C-erbB-2,P53,Ki-67 between breast mucinous carcinoma and invasive ductal carcinoma-not otherwise specified
原文传递
导出
摘要 目的探讨乳腺黏液癌(MC)和普通型浸润性导管癌(IDC-NOS)的临床病理特征及ER、PR、C-erbB-2、P53、Ki-67表达的差异,认识乳腺黏液癌低度恶性的生物学行为。方法收集2009年1月至2011年12月我院收治并经病理科常规免疫组化检测ER、PR、C-erbB-2、P53、Ki-67的MC病例20例和IDC-NOS病例60例。分析不同组患者的年龄、肿物大小、淋巴结转移情况、临床分期以及免疫组化指标表达情况。结果 (1)MC在肿块大小、淋巴结转移以及临床分期方面均明显不同于IDC-NOS,前者肿块较小,淋巴结转移率低,临床分期多为早期;(2)MC中ER、PR表达率显著高于IDC-NOS,C-erbB-2、P53和Ki-67阳性率显著低于IDC-NOS。结论 MC是一种低度恶性、低侵袭性的肿瘤,其激素水平较高,增殖活性较低。 Objective To explore the differences of the clinicopathological characteristics and expression of ER,PR,C-erbB-2,P53,Ki-67 between breast mucinous carcinoma(MC)and invasive ductal carcinoma-not otherwise specified(IDC-NOS).Methods The data of 20 cases of MC and 60 cases of IDC-NOS from Jan 2009 to Dec 2011 were collected,and immunohistochemical detections of ER,PR,C-erbB-2,P53 and Ki-67 were performed.The ages of patients,tumor sizes,metastasis of lymphnode and TNM staging were analyzed.Results (1)The tumor sizes,metastasis of lymphnode and TNM staging of MC were different from those of IDC-NOS.The MC showed smaller volumes,lower incidence of lymphnode metastasis and earlier TNM staging.(2)The positive rate of ER and PR were higher in MC,and those of C-erbB-2,P53 and Ki-67 were lower in MC.Conclusions MC have more favorable pathological characteristics than IDC-NOS with lower hormone levels and higher proliferative activity.
出处 《中华临床医师杂志(电子版)》 CAS 2012年第14期3909-3913,共5页 Chinese Journal of Clinicians(Electronic Edition)
基金 郑州大学第一附属医院青年创新基金项目
关键词 乳腺肿瘤 腺癌 黏液 受体 雌激素 孕激素受体 受体 erbB-2 肿瘤抑制蛋白质P53 KI-67抗原 Breast neoplasms Adenocarcinoma,mucinous Receptors,estrogen Progestins receptors Receptor,erbB-2 Tumor suppressor protein p53 Ki-67 antigen
  • 相关文献

参考文献5

二级参考文献27

  • 1<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:163
  • 2宁连胜.乳腺粘液癌[J].中国肿瘤临床,1981,8:148-149.
  • 3Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 2007,25 ( 33 ) : 5287-5312.
  • 4Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol,2007,25( 1 ) :118-145.
  • 5Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol,2006,19(4) :481-487.
  • 6Gong Y, Sweet W, Duh YJ, et al. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol,2009,131 (4) :490-497.
  • 7Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch ,2007,451 ( 1 ) : 19-25.
  • 8Pedersen M, Rasmussen BB. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Diagn Mol Pathol,2009,18 (2) :96-102.
  • 9Yaziji H, Gown AM. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet? Hum Pathol, 2004, 35 (2): 143-146.
  • 10Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologie considerations. J Clin Oncol, 2009,27 (8) : 1323- 1333.

共引文献218

同被引文献90

  • 1陶楚楚,王霞,马含夕,邢肖肖.不同类型的乳腺黏液癌超声声像图与病理学特征分析[J].影像研究与医学应用,2019,3(14):39-41. 被引量:9
  • 2周波,乔新民,杨德启,佟富中,钱利华,李建国.乳腺黏液癌的声像图特点及病理学基础[J].中国医学影像技术,2004,20(12):1806-1808. 被引量:11
  • 3彭玉兰,魏兵,吕青,马步云,周琛云,卢强,李宏江.乳腺粘液腺癌的超声诊断及误诊[J].华西医学,2007,22(2):254-255. 被引量:30
  • 4孙希印,周晓秋,高虹,李新功.P-gp、GST-π、TopoⅡ、p53在乳腺癌中的表达及相关性[J].中国现代普通外科进展,2007,10(3):224-226. 被引量:9
  • 5Memis A, Ozdemir N, Parildar M, et al. Mucinous (colloid) breast cancer: Mmammographic and US features with histologic correlation. Eur Radiol, 2000,35(1):39-43.
  • 6Liu H, Jiang YX, Liu JB, et al. Contrast-enhanced breast ultrasonography: Imaging features with histopathologic correlation. J Ultrasound Med, 2009,28(7):911-920.
  • 7Mori M, Tsunoda H, Kawauchi N, et al. Elastographic evaluation of mucinous carcinoma of the breast. Breast Cancer, 2012,19(1):60-63.
  • 8Hanagiri T, Ono K, Baba T, et al. Clinicopathologic characteristics of mucinous carcinoma of the breast. Int Surg, 2010,95(2):126-129.
  • 9Gown AM, Goldstein LC. The knowns and the unknowns in HER2 testing in breast cancer. Am J Clin Pathol, 2011,136(1):5-6.
  • 10Capella C, Eusebi V, Mann B, et al. Endocrine differentiation in mucoid carcinoma of the breast. Histopathology, 1980,4(6):613-630.

引证文献10

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部